REG - hVIVO PLC - Director/PDMR Shareholding

hVIVOAnnouncement

07/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250307:nRSG7322Za&default-theme=true

RNS Number : 7322Z  hVIVO PLC  07 March 2025

 
hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Director/PDMR Shareholding

& Total Voting Rights

 

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research
Organisation (CRO) and the world leader in human challenge clinical trials,
was notified on 6 March 2025 that 6,440,119 options were exercised by Yamin
Khan under the terms of the Company's Long Term Incentive Plan ("LTIP") at
£0.001 per ordinary share.

 

Of the 6,440,119 options exercised, Mr Khan has sold 3,062,246 ordinary shares
of £0.001 each in the Company ("Ordinary Shares") at 17p per Ordinary Share
to meet the exercise cost and tax liabilities. Following this transaction, Mr
Khan's holding in the Company is as detailed below:

 

 PDMR             Number of Ordinary Shares previously held  Number of options exercised  Number of options held post exercise  Number of Ordinary Shares sold  Resulting holding of Ordinary Shares  Resulting holding of Ordinary Shares %

 Yamin 'Mo' Khan  523,730                                    6,440,119                    4,606,794                             3,062,246                       3,901,603                             0.57%

 

Application will be made for 6,440,119 new Ordinary Shares to be admitted to
trading on AIM. Admission is expected to become effective on 13 March 2025.
Following Admission, the Company will have 686,811,996 Ordinary Shares in
issue. All Ordinary Shares shall have equal voting rights and none of the
Ordinary Shares are held in treasury. The total number of voting rights in the
Company immediately following Admission will therefore be 686,811,996.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Camilla Hume, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Phillip Marriage /               +44 (0)7980 541 893 / +44 (0)7867 984 082 /

Louis Ashe-Jepson
+44 (0)7747 515 393

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (Ticker: HVO) is a rapidly growing early-stage
Contract Research Organisation (CRO) and the global leader in human challenge
trials. The company delivers end-to-end clinical development services to a
diverse and expanding client base, including seven of the world's ten largest
biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/) brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development Consulting
and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp (https://flucamp.com/) . Additionally, its five clinical sites support
outpatient Phase II and III trials, ensuring a seamless and efficient pathway
from discovery to late-stage development.

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Yamin 'Mo' Khan
 2   Reason for notification

 a.  Position/Status                                              Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         hVIVO plc
 b.  LEI                                                          213800VT5KBM7JLIV118
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification Code

                                                                  ISIN GB00B9275X97

 b.  Nature of the transaction                                    Exercise of Options held under the Company's Long Term Incentive Plan ("LTIP")
                                                                  and sale of resulting shares
 c.  Price(s) and volume(s)                                                        No. of Shares  Price

                                                            Option exercise  6,440,119      £0.001
                                                                  Sale             3,062,246      £0.17

 d.  Aggregated information

     - Aggregated Volume                                          See above

     - Price
 e.  Date of the transaction                                      Exercise: 6 March 2025

                                                                  Sale: 6 March 2025

 f.  Place of the transaction                                     Option exercise: Outside a trading venue

                                                                  Sale: London Stock Exchange, AIM Market (XLON)

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

See above

e.

Date of the transaction

Exercise: 6 March 2025

 

Sale: 6 March 2025

 

 

f.

Place of the transaction

Option exercise: Outside a trading venue

Sale: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFQLLBEXLLBBK